The site is part of Thermo Fisher Scientific’s strategy to ensure a reliable supply of critical materials for new biologics and vaccines, and is further to a $600m investment in bioprocessing production capabilities announced in March this year.
The Nashville facility will be one of the world's largest SUT manufacturing sites and will more than double the company's SUT manufacturing capacity. The first phase of construction will be operational by the second quarter of 2022.
"Over the last few years, more and more biological drugs and vaccines are being manufactured utilizing the single use platform. This has created incredible demand for our SUT products," said Michel Lagarde, executive vice president of Thermo Fisher Scientific. "The site in Nashville will be critical in Thermo Fisher's global network to continue to support the biopharma industry's work in developing life-saving biologics and vaccines."
Thermo Fisher's wider investment in bioprocessing production capabilities stretches across 11 manufacturing sites in North America, Europe and Asia. Additional capacity will be added in 2021 with the completion of expansion projects in Logan, Utah, Suzhou, China, and a new SUT manufacturing site in Singapore.
The investment program also expands global production capabilities in additional bioprocessing manufacturing networks.
Capacity expansion projects in Grand Island, New York; Miami, Florida; and Inchinnan, Scotland are set to increase production capacity for Gibco cell culture media, supplements, and process liquids as well as the manufacturing of customer-owned proprietary media formulations.
Thermo Fisher's purification network, which specializes in the production of process-scale chromatography resins for applications including vaccines and gene therapies, continues to progress in capacity expansion efforts at its POROS resin manufacturing site in Bedford, Massachusetts and is nearing completion of the first phase of construction at its new site in Chelmsford, Massachusetts.